Please Wait
Applying Filters...
menu
    • menu
    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Jai Radhe Sales is your partner for all your sourcing needs.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Denosumab

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Filters Filter
    Cross PopUp
    FILTER :

    filter clear-filterReset all filters

    01 7Pralia

    02 10Prolia

    03 7Ranmark

    04 13Xgeva

    PharmaCompass
    ListList of Suppliers
    refreshReset Filter
    refresh Reset Filter
    Price Info Price Info
    product-page Product Main Page

    01

    Brand Name : Ranmark

    Denosumab

    arrow
    Fi Europe 2024
    Not Confirmed

    Brand Name : Ranmark

    Japan
    arrow
    Fi Europe 2024
    Not Confirmed

    Daiichi Sankyo

    Denosumab

    Main Therapeutic Indication : Musculoskeletal

    Currency : USD

    2020 Revenue in Millions : 172

    2019 Revenue in Millions : 162

    Growth (%) : 6

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    Brand Name : Xgeva

    Denosumab

    arrow
    Fi Europe 2024
    Not Confirmed

    Brand Name : Xgeva

    U.S.A
    arrow
    Fi Europe 2024
    Not Confirmed

    Amgen

    Denosumab

    Main Therapeutic Indication : Oncology

    Currency : USD

    2020 Revenue in Millions : 1,899

    2019 Revenue in Millions : 1,935

    Growth (%) : -2

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    Brand Name : Pralia

    Denosumab

    arrow
    Fi Europe 2024
    Not Confirmed

    Brand Name : Pralia

    Japan
    arrow
    Fi Europe 2024
    Not Confirmed

    Daiichi Sankyo

    Denosumab

    Main Therapeutic Indication : Musculoskeletal

    Currency : USD

    2020 Revenue in Millions : 303

    2019 Revenue in Millions : 281

    Growth (%) : 8

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    Brand Name : Prolia

    Denosumab

    arrow
    Fi Europe 2024
    Not Confirmed

    Brand Name : Prolia

    U.S.A
    arrow
    Fi Europe 2024
    Not Confirmed

    Amgen

    Denosumab

    Main Therapeutic Indication : Musculoskeletal

    Currency : USD

    2020 Revenue in Millions : 2,763

    2019 Revenue in Millions : 2,672

    Growth (%) : 3

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    05

    Brand Name : Pralia

    Denosumab

    arrow
    Fi Europe 2024
    Not Confirmed

    Brand Name : Pralia

    Japan
    arrow
    Fi Europe 2024
    Not Confirmed

    Daiichi Sankyo

    Denosumab

    Main Therapeutic Indication : Musculoskeletal

    Currency : USD

    2021 Revenue in Millions : 312

    2020 Revenue in Millions : 301

    Growth (%) : 12

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    06

    Brand Name : Xgeva

    Denosumab

    arrow
    Fi Europe 2024
    Not Confirmed

    Brand Name : Xgeva

    China
    arrow
    Fi Europe 2024
    Not Confirmed

    Beigene

    Denosumab

    Main Therapeutic Indication : Oncology

    Currency : USD

    2021 Revenue in Millions : 51

    2020 Revenue in Millions : 9

    Growth (%) : 441

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    07

    Brand Name : Prolia

    Denosumab

    arrow
    Fi Europe 2024
    Not Confirmed

    Brand Name : Prolia

    U.S.A
    arrow
    Fi Europe 2024
    Not Confirmed

    Amgen

    Denosumab

    Main Therapeutic Indication : Musculoskeletal

    Currency : USD

    2021 Revenue in Millions : 3,248

    2020 Revenue in Millions : 2,763

    Growth (%) : 18

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    08

    Brand Name : Ranmark

    Denosumab

    arrow
    Fi Europe 2024
    Not Confirmed

    Brand Name : Ranmark

    Japan
    arrow
    Fi Europe 2024
    Not Confirmed

    Daiichi Sankyo

    Denosumab

    Main Therapeutic Indication : Musculoskeletal

    Currency : USD

    2021 Revenue in Millions : 169

    2020 Revenue in Millions : 171

    Growth (%) : 6

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    09

    Brand Name : Xgeva

    Denosumab

    arrow
    Fi Europe 2024
    Not Confirmed

    Brand Name : Xgeva

    U.S.A
    arrow
    Fi Europe 2024
    Not Confirmed

    Amgen

    Denosumab

    Main Therapeutic Indication : Oncology

    Currency : USD

    2021 Revenue in Millions : 2,018

    2020 Revenue in Millions : 1,899

    Growth (%) : 6

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    10

    Brand Name : Pralia

    Denosumab

    arrow
    Fi Europe 2024
    Not Confirmed

    Brand Name : Pralia

    Japan
    arrow
    Fi Europe 2024
    Not Confirmed

    Daiichi Sankyo

    Denosumab

    Main Therapeutic Indication : Musculoskeletal

    Currency : USD

    2022 Revenue in Millions : 305

    2021 Revenue in Millions : 312

    Growth (%) : -3

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF